CAR T cell News and Research

RSS

Tails on engineered T cells could help fight cancer

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.

27 Jul 2023

Study offers new insights into why some CAR T-cells persist in children with leukemia

New insights explaining why some children have a longer remission than others after having cutting-edge CAR T-cell therapy for leukemia have been revealed by researchers at UCL, Great Ormond Street Hospital, and the Wellcome Sanger Institute.

6 Jul 2023

Using a vaccine to boost the response of engineered T cells

Engineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. However, it hasn't worked as well for solid tumors.

5 Jul 2023

First successful Phase 2 trial uses cutting-edge RNA CAR-T therapy to treat autoimmunity

Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

22 Jun 2023

New base-edited T-cells proven effective to treat lymphoblastic leukemia

Three young patients with relapsed T-cell leukemia have now been treated with base-edited T-cells, as part of a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

15 Jun 2023

OICR funding to help six Ontario-based research teams improve the lives of cancer patients

Funding announced today by the Ontario Institute for Cancer Research (OICR) will help six Ontario-based research teams pursue their ultimate goal of improving the lives of people with cancer.

14 Jun 2023

Study raises new hopes for blood cancer patients with an incomplete response to CAR T cell therapy

The aim of immunotherapy strategies is to use cells in the patient's own immune system to destroy tumor cells. CAR T cell therapy is an immunotherapy that is effective in treating blood cancer.

12 Jun 2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.

5 Jun 2023

New approach to CAR T-cell therapy shows promise against small cell lung cancer in preclinical study

A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study.

25 Apr 2023

First-in-human clinical study begins investigating the duoCAR T-cell therapy for treatment of HIV

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy.

19 Apr 2023

Researchers discover the molecule responsible for guiding T cells toward tumors

Immunotherapy, particularly CAR T-Cell treatment for cancer, is extending the lives of many patients. But sometimes the therapy randomly migrates to places it shouldn't go, tucking into the lungs or other noncancerous tissue and causing toxic side effects.

18 Apr 2023

CAR T-cell therapy improves quality of life for patients with blood cancers

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed cancer treatment, yet relatively few studies have investigated the impact of the therapy on longitudinal patient quality of life – an aspect of care that often suffers from receiving traditional intensive cancer medications, such as chemotherapy.

30 Mar 2023

$3.2 million grant aids in the study of genetic testing approach to close racial disparity gaps in cancer care

With the aid of a near $3.2 million National Cancer Institute grant (R01CA277599) recently awarded, investigators from the state's leading cancer program, Rutgers Cancer Institute of New Jersey,  and Georgetown University's Lombardi Comprehensive Cancer Center, both NCI-designated Comprehensive Cancer Centers, will work to close racial disparity gaps in cancer care delivery by examining a novel approach to genetic testing and care based on community-identified needs.

30 Mar 2023

Reprogrammed tumor cells could teach the body's immune system to fight cancer

Some cities fight gangs with ex-members who educate kids and starve gangs of new recruits. Stanford Medicine researchers have done something similar with cancer — altering cancer cells so that they teach the body's immune system to fight the very cancer the cells came from.

2 Mar 2023

University of Vermont Cancer Center to offer a novel, highly effective form of cancer treatment

The University of Vermont Cancer Center will offer a novel, highly effective form of cancer treatment called CAR T-cell therapy beginning in February, when final accreditation and approval to begin treating patients is expected.

24 Feb 2023

New type of immunotherapy effective in mice with ovarian cancer

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.

6 Feb 2023

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two major hallmarks of quality

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.

18 Jan 2023

Novel approach may prevent antibodies from triggering immune rejection of transplant cells

Researchers at UCSF have developed a novel, potentially life-saving approach that may prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells.

2 Jan 2023

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

A patient with relapsed T cell leukemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

12 Dec 2022

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

Investigators from Rutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Cancer Center and leading cancer program along with Tufts Medical Center in Boston, developed and validated the Advanced-stage Hodgkin lymphoma International Prognostication Index (A-HIPI).